|
|
The neuroprotective effects of caffeine on the mice model of Parkinson’s disease: a transcriptomic analysis |
Zheng Yuyin1, Feng Yijia2, Ruan Qingqing2, Tu Wenzhan1 |
1.Department of Rehabilitation Medicine, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, China; 2.Department of Neurology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, China |
|
Cite this article: |
Zheng Yuyin,Feng Yijia,Ruan Qingqing, et al. The neuroprotective effects of caffeine on the mice model of Parkinson’s disease: a transcriptomic analysis[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2021, 51(6): 444-448,453.
|
|
Abstract Objective: To investigate by transcriptomics the possible molecular mechanism of the protective effect of caffeine in Parkinson’s disease, so as to provide new evidence for elucidating the neuroprotective effect of caffeine. Methods: The mice were injected with α-synuclein (α-Syn) fibril in the hippocampal region by stereotaxic injection, and were fed with caffeine. Three months later, the hippocampus tissues were isolated for transcriptome sequencing (RNA-seq). Results: α-synuclein was obviously aggregated in hippocampus and impaired the working memory in mice (P<0.05). Long-term drinking caffeine could effectively improve the cognitive impairment caused by α-Synuclein in mice (P<0.05). The transcriptome changes induced by α-Synuclein were mainly enriched in the pathways of microglial activation and chemokines signaling. Chronic caffeine consumption significantly improved the cell proliferation (P<0.05). Conclusion: Caffeine may repair the neuronal inflammatory damage caused by α-Syn via promoting cell proliferation.
|
Received: 02 September 2020
|
|
|
|
|
参考文献:
[1] GOEDERT M. Alpha-synuclein and neurodegenerative diseases[J]. Nat Rev Neurosci, 2001, 2(7): 492-501.
[2] GOUD K Y, MOONLA C, MISHRA R K, et al. Wearable electrochemical microneedle sensor for continuous monitoring of levodopa: toward parkinson management[J]. ACS Sens, 2019, 4(8): 2196-2204.
[3] HAVELUND J F, ANDERSEN A D, BINZER M, et al. Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia[J]. J Neurochem, 2017, 142(5): 756-766.
[4] YOOSEFIAN M, RAHMANIFAR E, ETMINAN N. Nanocarrier for levodopa Parkinson therapeutic drug; comprehensive benserazide analysis[J]. Artif Cells Nanomed Biotechnol, 2018, 46(sup1): 434-446.
[5] GROSSO G, GODOS J, GALVANO F, et al. Coffee, caffeine, and health outcomes: An umbrella review[J]. Annu Rev Nutr, 2017, 37: 131-156.
[6] HIGDON J V, FREI B. Coffee and health: a review of recent human research[J]. Crit Rev Food Sci Nutr, 2006, 46(2): 101-123.
[7] COSTENLA A R, CUNHA R A, Mendonça A D. Caffeine, adenosine receptors, and synaptic plasticity[J]. J Alzheimers Dis, 2010, 20 Suppl 1: S25-S34.
[8] LUAN Y, REN X, ZHENG W, et al. Chronic caffeine treatment protects against alpha-synucleinopathy by reestablishing autophagy activity in the mouse striatum[J]. Front Neurosci, 2018, 12: 301.
[9] HU Q, REN X, LIU Y, et al. Aberrant adenosine A2A receptor signaling contributes to neurodegeneration and cognitive impairments in a mouse model of synucleinopathy [J]. Exp Neurol, 2016, 283(Pt A): 213-223.
[10] ZHENG W, ZHOU J, LUAN Y, et al. Spatiotemporal control of GPR37 signaling and its behavioral effects by optogenetics [J]. Front Mol Neurosci, 2018, 11: 95.
[11] VOLPICELLI-DALEY L A, LUK K C, PATEL T P, et al. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death [J]. Neuron, 2011, 72(1): 57-71.
[12] LUK K C, KEHM V M, ZHANG B, et al. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice[J]. J Exp Med, 2012, 209(5): 975-986.
[13] LUK K C, KEHM V K, CARROLL J, et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice[J]. Science, 2012, 338(6109): 949-953.
[14] SONG N, CHEN L, XIE J. Alpha-synuclein handling by microglia: activating, combating, and worsening[J]. Neurosci Bull, 2021, 37(5): 751-753.
[15] CHENG B, LI X, DAI K, et al. Triggering receptor expressed on myeloid cells-2 (TREM2) interacts with colony-stimulating factor 1 receptor (CSF1R) but is not necessary for CSF1/CSF1R-mediated microglial survival[J]. Front Immunol, 2021, 12: 633796.
[16] WANG C, XIONG M, GRATUCE M, et al. Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia[J]. Neuron, 2021, S0896-6273(21)00194-X.
[17] WANG J, CHEN Z, WALSTON J D, et al. Alpha-Synuclein activates innate immunity but suppresses interferon-gamma expression in murine astrocytes[J]. Eur J Neurosci, 2018, 48(1): 1583-1599.
[18] OLANOW C W, SAVOLAINEN M, CHU Y, et al. Temporal evolution of microglia and α-synuclein accumulation following foetal grafting in Parkinson's disease[J]. Brain, 2019, 142(6): 1690-1700.
[19] RUAN C, SUN L, KROSHILINA A, et al. A novel Tmem119-tdTomato reporter mouse model for studying microglia in the central nervous system[J]. Brain Behav Immun, 2020, 83: 180-191.
[20] KAISER T, FENG G. Tmem119-EGFP and tmem119-CreERT2 transgenic mice for labeling and manipulating microglia[J]. eNeuro, 2019, 6(4): ENEURO.0448-18. 2019.
[21] ALE-AGHA N, GOY C, JAKOBS P, et al. CDKN1B/p27 is localized in mitochondria and improves respiration-dependent processes in the cardiovascular system-New mode of action for caffeine[J]. PLoS Biol, 2018, 16(6): e2004408.
[22] SPYRIDOPOULOS I, FICHTLSCHERER S, POPP R, et al. Caffeine enhances endothelial repair by an AMPK-dependent mechanism[J]. Arterioscler Thromb Vasc Biol, 2008, 28(11): 1967-1974. |
|
|
|